Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1483956
This article is part of the Research Topic Biomarkers of Immunotoxicity from Immune Checkpoint Inhibitors View all 13 articles

Eosinophil is a Predictor of Severe Immune-Related Adverse Events Induced by Ipilimumab plus Nivolumab Therapy in Patients with Renal Cell Carcinoma: A Retrospective

Provisionally accepted
Yoshihiko Tasaki Yoshihiko Tasaki 1Shuzo Hamamoto Shuzo Hamamoto 1*Shimpei Yamashita Shimpei Yamashita 2Junya Furukawa Junya Furukawa 3Kazutoshi Fujita Kazutoshi Fujita 4Ryotaro Tomida Ryotaro Tomida 3Makito Miyake Makito Miyake 5Noriyuki Ito Noriyuki Ito 6Hideto Iwamoto Hideto Iwamoto 7Yoshihisa Mimura Yoshihisa Mimura 1Yosuke Sugiyama Yosuke Sugiyama 1Rei Unno Rei Unno 1Atsushi Okada Atsushi Okada 1Takahiro Yasui Takahiro Yasui 1Yoko Furukawa-Hibi Yoko Furukawa-Hibi 1
  • 1 Nagoya City University, Nagoya, Japan
  • 2 Wakayama Medical University, Wakayama, Wakayama, Japan
  • 3 Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Tokushima, Japan
  • 4 Kindai University, Higashi-osaka, Ōsaka, Japan
  • 5 Nara Medical University, Kashihara, Nara, Japan
  • 6 Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan
  • 7 Faculty of Medicine, Tottori University, Yonago, Tottori, Japan

The final, formatted version of the article will be published soon.

    Introduction: Immune-related adverse events (irAEs) induced by immune checkpoint inhibitors are difficult to predict and can lead to severe events. Although it is important to develop strategies for the early detection of severe irAEs, there is a lack of evidence on irAEs associated with ipilimumab plus nivolumab therapy for metastatic renal cell carcinoma (RCC). Therefore, this study aimed to investigate the association between eosinophil and severe irAEs in patients receiving ipilimumab plus nivolumab therapy for RCC.Methods: In this retrospective study, 161 patients receiving ipilimumab plus nivolumab therapy for RCC were divided into three groups based on whether they experienced

    Keywords: eosinophil, ipilimumab, Nivolumab, Immune-related adverse event, Renal cell carcinoma

    Received: 20 Aug 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Tasaki, Hamamoto, Yamashita, Furukawa, Fujita, Tomida, Miyake, Ito, Iwamoto, Mimura, Sugiyama, Unno, Okada, Yasui and Furukawa-Hibi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Shuzo Hamamoto, Nagoya City University, Nagoya, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.